Screener
Halozyme Therapeutics HALO Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total liabilities | 2,433,865 | 2,476,509 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity | ||
| Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock - $0.001 par value; 300,000 shares authorized; 114,042 and 117,782 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 114 | 118 |
| Additional paid-in capital | — | 12,002 |
| Accumulated other comprehensive loss | (7,830) | (18,092) |
| Retained earnings | 151,259 | 54,786 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's preferred stock, shares authorized?
- Halozyme Therapeutics (HALO) reported preferred stock, shares authorized of $20M in Q2 2026.
- How has Halozyme Therapeutics's preferred stock, shares authorized changed year-over-year?
- Halozyme Therapeutics's preferred stock, shares authorized decreased by 0.0% year-over-year, from $20M to $20M.
- What is the long-term trend for Halozyme Therapeutics's preferred stock, shares authorized?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $20M to $20M.
- What does preferred stock, shares authorized mean?
- Preferred Stock, Shares Authorized
Ask your AI about Halozyme Therapeutics's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude